Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

7.96
-0.6800-7.87%
Post-market: 7.95-0.0100-0.13%17:10 EDT
Volume:722.23K
Turnover:5.84M
Market Cap:108.26M
PE:-1.99
High:8.87
Open:8.69
Low:7.76
Close:8.64
52wk High:17.43
52wk Low:5.06
Shares:13.60M
Float Shares:11.92M
Volume Ratio:1.49
T/O Rate:6.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9979
EPS(LYR):-6.2414
ROE:-138.17%
ROA:-66.80%
PB:0.85
PE(LYR):-1.28

Loading ...

Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate

Benzinga Earnings
·
Aug 11

Immunic reports Q2 EPS (80c), consensus ($1.16)

TIPRANKS
·
Aug 11

Immunic Q2 Net Loss Widens to $34.1 Million; Operating Expenses Rise to $35.3 Million

Reuters
·
Aug 11

Immunic Files Form 3 for Director Elena Ridloff, Reporting no Beneficial Ownership

Reuters
·
Aug 11

Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets

Dow Jones
·
Aug 11

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Immunic Inc Expected to Post a Loss of $1.19 a Share - Earnings Preview

Reuters
·
Aug 03

Immunic Updates Corporate Strategy, Highlights Vidofludimus Plans

TIPRANKS
·
Jul 15

Immunic Publishes Investor Presentation Outlining Vidofludimus Calcium Phase 3 Program in Multiple Sclerosis

Reuters
·
Jul 14

Immunic Names CEO Erik Lundgren to Board After Tamar Howson Retirement Resignation

Reuters
·
Jul 07

Immunic Holds Annual Shareholder Meeting, Backs 6 Million-share Increase to Equity Plan

Reuters
·
Jun 30

Immunic joins H.C. Wainwright Neuro Perspectives Expert Summit fireside chat

Reuters
·
Jun 10

Immunic files Form 3 initial beneficial ownership statement for CEO Erik Lundgren

Reuters
·
Jun 02

Immunic publishes investor presentation on oral immunology pipeline led by vidofludimus calcium in multiple sclerosis

Reuters
·
Jun 01

Stifel Nicolaus Reaffirms Their Buy Rating on Immunic (IMUX)

TIPRANKS
·
May 29

Immunic presents new Phase 2 CALLIPER analyses of vidofludimus calcium in progressive multiple sclerosis at CMSC 2026

Reuters
·
May 28

Eqs-News: Immunic to Present Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium at the Cmsc Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

THOMSON REUTERS
·
May 28

Immunic Appoints New CEO to Lead MS Strategy

TIPRANKS
·
May 27

Immunic names ex-Genentech executive Erik Lundgren CEO, replacing Daniel Vitt

Reuters
·
May 27

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

THOMSON REUTERS
·
May 27